Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD-001 in Advanced Solid Tumors
NCT06801470Phase 1Recruiting
- Sponsor
- CD Biopharma
- Start
- Jan 2025
- Primary completion
- Jan 2028
- Modality
- Fc Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of CD-001 in solid tumor, sponsored by CD Biopharma. Primary endpoints: Number of Participants with Dose Limiting Toxicities at 28 days, Incidence of Adverse Events and Serious Adverse Events at 3 years and 1 more. Started Jan 2025; status: recruiting.
02
Drugs
CD-001
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06801470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06801470.